COVID-19 and Hartnup disease: an affair of intestinal amino acid malabsorption.
Eat Weight Disord
; 26(5): 1647-1651, 2021 Jun.
Article
Dans Anglais
| MEDLINE | ID: covidwho-655703
ABSTRACT
Since the outbreak of COVID-19, clinicians have tried every effort to fight the disease, and multiple drugs have been proposed. However, no proven effective therapies currently exist, and different clinical phenotypes complicate the situation. In clinical practice, many severe or critically ill COVID-19 patients developed gastrointestinal (GI) disturbances, including vomiting, diarrhoea, or abdominal pain, even in the absence of cough and dyspnea. Understanding the mechanism of GI disturbances is warranted for exploring better clinical care for COVID-19 patients. With evidence collected from clinical studies on COVID-19 and basic research on a rare genetic disease (i.e., Hartnup disorder), we put forward a novel hypothesis to elaborate an effective nutritional therapy. We hypothesize that SARS-CoV-2 spike protein, binding to intestinal angiotensin-converting enzyme 2, negatively regulates the absorption of neutral amino acids, and this could explain not only the GI, but also systemic disturbances in COVID-19. Amino acid supplements could be recommended.Level of evidence No level of evidence Hypothesis article.
Mots clés
Texte intégral:
Disponible
Collection:
Bases de données internationales
Base de données:
MEDLINE
Sujet Principal:
Maladies gastro-intestinales
/
COVID-19
/
Acides aminés
/
Maladie de Hartnup
Type d'étude:
Étude observationnelle
/
Étude pronostique
Les sujets:
Covid long
Limites du sujet:
Humains
langue:
Anglais
Revue:
Eat Weight Disord
Thème du journal:
Gastroentérologie
/
Métabolisme
Année:
2021
Type de document:
Article
Pays d'affiliation:
S40519-020-00963-y
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS